NurExone Biologic Inc. Announces Third Quarter 2025 Financial Results and Provides Corporate Update

Executive Summary

• NurExone reported Q3 2025 unaudited results, posting a net loss of US$1.47 M (up from US$1.25 M YoY).
• The company exercised 8.2 M warrants, generating approximately C$3.2 M in gross proceeds and completed two private placements raising ~C$1.4 M for working capital and clinical development.
• Significant pre‑clinical milestones were disclosed: dose‑dependent vision recovery in a glaucoma model and motor recovery in an acute spinal cord injury model; plus U.S. and Israeli patent allowances for its exosome manufacturing process and the establishment of a new U.S. GMP facility in Indianapolis with a US$0.26 M incentive.

Key Details

• Warrant Exercise: 8.2 M warrants (2023‑2024) accelerated on Oct 8 2025, exercised by Nov 7 2025 → C$3.2 M gross proceeds for general corporate and working capital.
• Private Placements:
• Aug 20 2025 – 1,258,072 units @ C$0.62/unit → C$0.8 M gross; each unit = 1 common share + ½ warrant (exercise price C$0.80, 36‑mo).
• Sep 11 2025 – 930,376 units @ C$0.68/unit → C$0.6 M gross; each unit = 1 common share + ½ warrant (exercise price C$0.88, 36‑mo).
• Use of Proceeds: Primarily working capital, general corporate purposes, and clinical development activities.
• Patent Activity: U.S. Notice of Allowance for exosome manufacturing process (3D scaffold & shear‑stress bioreactor) received Sep 8 2025; Israeli patent granted Sep 11 2025; formal grant in Israel on Nov 11 2025.
• U.S. Manufacturing Incentive: Up to US$0.26 M incentive secured for new GMP exosome facility (Exo‑Top Inc.) in Indianapolis, Indiana.
• Preclinical Data Highlights:
• Glaucoma model – dose‑dependent retinal function recovery to near‑baseline STR‑ERG; improved ganglion cell survival.
• Acute spinal cord injury model – 100 % of high‑dose animals regained measurable hind‑limb walking (CatWalk XT analysis).
• Equity Incentives:
• RSUs: 1,450,000 units granted Nov 27 2025 (vest on first anniversary).
• Stock Options: 271,700 options granted Nov 27 2025 at C$0.75 exercise price; vesting schedule over 24 months with cliff and quarterly tranches.
• Financial Metrics (Q3 2025 vs Q3 2024):
• R&D expense: US$0.70 M ↑ US$0.20 M (higher headcount & stock‑based comp).
• G&A expense: US$0.76 M ↓ US$0.02 M (lower service costs).
• Net financial income: US$0.01 M ↓ from US$0.04 M.
• Management Commentary: CEO Dr. Lior Shaltiel highlighted patent approvals, preclinical progress, and preparation for first‑in‑human trials; CFO Eran Ovadya emphasized disciplined execution supported by recent financing.

Notable Quotes

“During this quarter, we strengthened our platform with new patent approvals … these developments further support our long‑term strategy as we prepare ExoPTEN for first‑in‑human evaluation.” – Dr. Lior Shaltiel, CEO

“We executed our operating plan with discipline, supported by strengthened working capital from the August and September Offerings.” – Eran Ovadya, CFO